Literature DB >> 23429734

Therapeutic resistance: ALL-important mutations.

Sarah Seton-Rogers.   

Abstract

Year:  2013        PMID： 23429734     DOI： 10.1038/nrc3478

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  2 in total

1.  Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

Authors:  Gannie Tzoneva; Arianne Perez-Garcia; Zachary Carpenter; Hossein Khiabanian; Valeria Tosello; Maddalena Allegretta; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Maddalena Paganin; Giuseppe Basso; Jana Hof; Renate Kirschner-Schwabe; Teresa Palomero; Raul Rabadan; Adolfo Ferrando
Journal:  Nat Med       Date:  2013-02-03       Impact factor: 53.440

2.  Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.

Authors:  Julia A Meyer; Jinhua Wang; Laura E Hogan; Jun J Yang; Smita Dandekar; Jay P Patel; Zuojian Tang; Paul Zumbo; Sheng Li; Jiri Zavadil; Ross L Levine; Timothy Cardozo; Stephen P Hunger; Elizabeth A Raetz; William E Evans; Debra J Morrison; Christopher E Mason; William L Carroll
Journal:  Nat Genet       Date:  2013-02-03       Impact factor: 38.330
  2 in total
  1 in total

1.  Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine.

Authors:  Alphy Rose-James; R Shiji; P Kusumakumary; Manjusha Nair; Suraj K George; T T Sreelekha
Journal:  Med Oncol       Date:  2016-07-23       Impact factor: 3.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.